Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
January 09, 2023 07:00 ET
|
Instil Bio
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical...
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
December 08, 2022 07:00 ET
|
Instil Bio
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC,...
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 16:07 ET
|
Instil Bio
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1’23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First...
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 08, 2022 07:00 ET
|
Instil Bio
DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
October 31, 2022 07:00 ET
|
Instil Bio
Voluntarily paused enrollment in ITIL-168 and ITIL-306 trials pending outcome of manufacturing analysis and implementation of corrective actionsNo regulatory agency, including the FDA, has notified...
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
October 18, 2022 07:00 ET
|
Instil Bio
• ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate receptor alpha which is designed to boost TIL activity in the tumor microenvironment • CoStAR-T...
Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit
September 19, 2022 07:20 ET
|
Instil Bio
DALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
Instil Bio to Present at Morgan Stanley Global Healthcare Conference
September 09, 2022 07:00 ET
|
Instil Bio
DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer
September 06, 2022 07:00 ET
|
Instil Bio
DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 12, 2022 07:00 ET
|
Instil Bio
Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational...